Acute myocardial infarction (AMI), commonly known as a heart attack, remains a leading cause of mortality in developed nations. Globally, nearly 3 million individuals are affected by this condition, with over a million deaths occurring annually in the United States alone. This activity is designed for healthcare professionals to improve their proficiency in the Diagnosis Ami and subsequent management. Effective diagnosis AMI is the cornerstone of timely intervention and improved patient outcomes. Upon completion of this activity, clinicians will be better equipped to recognize AMI signs and symptoms, utilize diagnostic tools to assess severity and damage, apply evidence-based management strategies, and collaborate within a multidisciplinary team for holistic patient care. By focusing on enhancing skills in prompt recognition and effective management, this resource aims to bridge the practice gap and improve competencies in addressing acute myocardial infarction.
Objectives:
- Enhance the ability to identify the signs and symptoms of acute myocardial infarction through thorough patient evaluations and accurate interpretation of diagnostic findings, crucial for effective diagnosis AMI.
- Improve skills in assessing the severity and extent of myocardial damage using a range of diagnostic tests, including electrocardiography (ECG), cardiac biomarkers, and advanced imaging techniques, all vital for precise diagnosis AMI.
- Strengthen the application of evidence-based guidelines and best practices in AMI management, encompassing both pharmacological and interventional therapies, following accurate diagnosis AMI.
- Foster effective collaboration within a multidisciplinary healthcare team, including cardiologists, nurses, and rehabilitation specialists, to ensure comprehensive care and achieve optimal outcomes for patients after diagnosis AMI.
Introduction
Acute myocardial infarction (AMI) is a critical condition characterized by irreversible damage to the heart muscle due to a severe reduction or cessation of oxygen supply. Its prevalence underscores the urgent need for healthcare professionals to be adept at diagnosis AMI and initiating prompt treatment. AMI is broadly classified into two main types: non–ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). It’s important to differentiate NSTEMI from unstable angina, which presents similarly but lacks elevated cardiac markers.[1][2][3]
Myocardial infarction results in permanent damage to the myocardium, impacting both diastolic and systolic heart function and significantly elevating the risk of arrhythmias and other serious complications. The cornerstone of improving prognosis in AMI is rapid reperfusion, restoring blood flow to the affected heart muscle as quickly as possible. Treatment initiated within the first 6 hours of symptom onset dramatically improves patient outcomes, highlighting the critical importance of early and accurate diagnosis AMI.
The diagnosis AMI is confirmed when at least two of the following criteria are met:
- Clinical symptoms indicative of myocardial ischemia.
- New ST-segment deviations on ECG or the presence of a new left bundle branch block (LBBB).
- Development of pathological Q waves on electrocardiogram (ECG).
- Identification of new regional wall motion abnormalities through cardiac imaging.
- Evidence of an intracoronary thrombus found during autopsy or angiography.
Etiology
The fundamental cause of acute myocardial infarction is a significant decrease in coronary blood flow. This reduction leads to an insufficient supply of oxygen to the heart muscle, resulting in cardiac ischemia. The mechanisms behind reduced coronary flow are diverse. The most common cause involves the rupture of atherosclerotic plaques, triggering thrombosis and acutely obstructing coronary blood flow. However, other etiologies for myocardial ischemia exist, including coronary artery embolism (accounting for approximately 2.9% of cases), cocaine-induced ischemia, coronary dissection, and coronary vasospasm.[4][5] Accurate diagnosis AMI requires consideration of these varied etiologies to guide appropriate management.
Nonmodifiable Risk Factors
- Sex
- Age
- Family history of coronary artery disease
- Male pattern baldness
Modifiable Risk Factors
- Cigarette smoking
- Dyslipidemia
- Diabetes mellitus
- Hypertension
- Obesity
- Sedentary lifestyle
- Poor oral hygiene
- Peripheral vascular disease
- Elevated homocysteine levels
Other Causes of MI
- Trauma
- Vasculitis
- Drug use, particularly cocaine
- Coronary artery anomalies
- Coronary artery emboli
- Aortic dissection
- Conditions causing increased cardiac demand such as hyperthyroidism and anemia
Epidemiology
Atherosclerotic plaque occlusion is responsible for approximately 70% of fatal AMI cases, underscoring the critical role of atherosclerosis in AMI development. Consequently, strategies for preventing atherosclerotic disease are central to AMI prevention. Modifiable risk factors are implicated in a significant majority of AMI cases, accounting for 90% in men and 94% in women. These key modifiable factors include smoking, physical inactivity, hypertension, obesity, elevated LDL cholesterol, and high triglyceride levels. In contrast, age, sex, and family history are nonmodifiable risk factors that increase susceptibility to atherosclerosis and AMI.[6][7] Understanding these epidemiological factors is crucial for risk assessment and preventative strategies, complementing effective diagnosis AMI in clinical practice.
Pathophysiology
The pathophysiology of AMI begins with the rupture of an atherosclerotic plaque within a coronary artery. This rupture initiates an inflammatory response, attracting monocytes and macrophages to the site. This inflammatory process leads to thrombus formation and platelet aggregation, further narrowing or completely obstructing the coronary artery. The resulting decrease in oxygen delivery to the myocardium leads to myocardial ischemia (see Image. Specimen Showing MI). The ischemic cascade ensues as the heart muscle’s ability to produce ATP in the mitochondria is compromised. This ultimately leads to apoptosis (cell death) of the endocardium and subsequent myocardial infarction. Effective diagnosis AMI is crucial to interrupt this pathological process and initiate timely interventions.
Coronary arteries generally have predictable territorial distributions, although genetic variations can occur. For instance, the left anterior descending artery supplies blood to the interventricular septum, the anterior and lateral walls, and the apex of the left ventricle. The left circumflex artery provides blood flow to the inferolateral wall, while the right coronary artery primarily supplies the right ventricle. The inferior wall of the heart can be supplied by either the left circumflex or the right coronary artery.[8] Understanding these vascular territories is important in interpreting ECG findings and localizing the area of infarction during diagnosis AMI.
Histopathology
The histological changes in myocardial infarction are time-dependent and evolve throughout the course of the disease. Immediately at time 0, no microscopic changes are discernible. Within the first 0.5 to 4 hours, light microscopy reveals waviness of muscle fibers at the tissue periphery, along with glycogen depletion. From 4 to 12 hours, coagulation necrosis and edema develop in the myocardium. Between 12 to 24 hours, the gross appearance of the tissue becomes dark and mottled, and histopathology shows contraction band necrosis and a predominance of neutrophils.
Subsequently, nuclear reduction becomes apparent between 1 to 3 days, and macrophages begin to appear within 3 to 7 days to clear apoptotic cells and tissue debris. Granulation tissue starts to form at 7 to 10 days, and collagen type I deposition occurs after 10 days. Ultimately, after approximately 2 months, the myocardium undergoes scarring. While histopathology is not typically used for acute diagnosis AMI, understanding these changes is crucial for interpreting biopsy results in certain clinical contexts and for research purposes.
History and Physical
History and physical examination alone are often insufficient for a definitive diagnosis AMI, but they are critical first steps in patient evaluation. The history should focus on the characteristics of the chest pain, including its onset, quality (e.g., pressure, tightness), location, radiation, and associated symptoms. Recent studies suggest that diaphoresis (sweating) and pain radiating bilaterally to the arms are more commonly reported by men experiencing MI. Other symptoms that may accompany AMI include:
- Lightheadedness
- Anxiety
- Cough
- Choking sensation
- Diaphoresis
- Wheezing
- Irregular heart rate
The physical examination should encompass vital signs, general appearance (noting diaphoresis), pulmonary auscultation, and cardiac auscultation. Key aspects of the physical examination include:
- Heart rate: Tachycardia, atrial fibrillation, or ventricular arrhythmias may be present, indicating electrical instability of the heart.
- Pulses: Unequal pulses may suggest aortic dissection, a critical differential diagnosis AMI.
- Blood pressure: Blood pressure is typically elevated initially in AMI but can become hypotensive if cardiogenic shock develops due to severe cardiac dysfunction.
- Respiratory findings: Tachypnea (rapid breathing) and fever may indicate an inflammatory response.
- Neck veins: Distended neck veins can indicate right ventricular failure and increased central venous pressure.
- Cardiac findings: The heart examination may reveal lateral displacement of the apical impulse, a soft S1 sound, a palpable S4 sound, and new murmurs such as mitral regurgitation. A loud holosystolic murmur radiating to the sternum may indicate ventricular septal rupture, a complication post-diagnosis AMI.
- Pulmonary findings: Wheezing and rales (crackles) may be heard if pulmonary edema has developed, indicating fluid overload in the lungs secondary to cardiac dysfunction.
- Extremities: Edema or cyanosis, along with coldness, may be present in the extremities due to compromised circulation.
Evaluation
Prompt and early ECG testing is paramount in all patients presenting with chest pain or symptoms suggestive of AMI. It is crucial to remember that women, older patients, and individuals with diabetes may present with atypical symptoms. Women, for example, may experience symptoms like abdominal pain or dizziness and may not have chest pain (see Image. Myocardial Infarction Warning Signs in Women). Older patients may more commonly present with shortness of breath rather than chest pain in MI. Any of these presentations should prompt immediate ECG testing to facilitate timely diagnosis AMI.[9][10][11]
The ECG is a highly specific tool for diagnosis AMI, with a specificity ranging from 95% to 97%. However, its sensitivity is lower, approximately 30%. Improving ECG sensitivity can be achieved by using right-sided and posterior lead placement, and by performing repeat ECGs. For example, peaked T-waves on ECG, known as “hyperacute T waves,” are early indicators of ischemia and often precede ST-segment elevation. ST-elevation findings, when present, are critical for diagnosis AMI. Specifically, ST-segment elevation greater than 2 mm in 2 contiguous leads (inferior leads II, III, aVF; septal leads V1, V2; anterior leads V3, V4; lateral leads I, aVL, V5, V6) is highly indicative of STEMI (see Image. ECG With Pardee Waves Indicating AMI). Reciprocal ST depressions in anatomically opposite regions of the myocardium are also frequently observed.
Diagnosis AMI, particularly STEMI, can be more challenging using ECG in patients with pre-existing left bundle branch block (LBBB) or pacemakers. However, specific criteria, such as the Sgarbossa criteria, have been developed to aid in diagnosis AMI in these situations. Sgarbossa criteria suggest that isolated ST elevations in lead aVR, in the appropriate clinical context, may indicate left main coronary artery occlusion. Wellens’ criteria, characterized by deeply biphasic T waves in leads V2 and V3, are predictive of a critical proximal left anterior descending artery occlusion, which can lead to extensive anterior wall myocardial infarction. Recognition of these ECG patterns is vital for accurate diagnosis AMI and prompt intervention.
Patients with MI symptoms may not always present with the classic ST-elevation ECG abnormalities. In cases where patients have typical chest pain but lack obvious ST elevation, further investigation for NSTEMI is essential. Subtle ECG changes, such as ST depressions and T-wave inversions, may be present. Serial ECGs can be valuable in detecting dynamic changes over time. Importantly, ECG findings may be non-diagnostic or show only non-specific changes in NSTEMI.
To aid clinicians in determining the need for further testing in patients without ST-elevation, diagnostic guidelines and risk scores are invaluable. Given the limited sensitivity of ECG for STEMI, cardiac troponin levels have become a near-universal diagnostic tool for patients with suspected MI. The HEART score is a validated and widely used risk stratification tool. It integrates clinical suspicion, patient risk factors, ECG findings, and troponin levels to categorize patients into different risk levels for adverse cardiac events. This structured approach significantly enhances the accuracy of diagnosis AMI and guides subsequent management decisions.
Laboratory Studies
For laboratory evaluation in suspected AMI, a cardiac troponin test should be the primary cardiac marker ordered. Additional relevant laboratory tests include a complete blood count (CBC), lipid profile, renal function tests, and a metabolic panel.
Cardiac biomarkers are particularly useful in the diagnosis AMI, especially in NSTEMI. The primary cardiac markers include troponin, creatine kinase-MB (CK-MB), and LDH.
Troponin tests are considered the most specific laboratory test for the early diagnosis AMI. The levels of troponin isoforms I and T are measured. Troponin levels typically peak around 12 hours after symptom onset and remain elevated for up to 7 days. High-sensitivity troponin assays, now approved for use in the United States after extensive use in Europe, offer increased sensitivity compared to conventional troponin assays. However, while more sensitive, high-sensitivity troponin assays are also less specific, potentially leading to more false-positive results.[3] Therefore, careful interpretation in the clinical context is crucial for accurate diagnosis AMI.
CK-MB, an isoenzyme of creatine kinase found predominantly in the myocardium, reaches its peak level around 10 hours after MI and typically normalizes within 2 to 3 days. Due to its lower specificity and rapid return to baseline, CK-MB is less clinically utilized in contemporary diagnosis AMI compared to troponin.
LDH levels peak much later, around 72 hours after MI, and return to normal within 10 to 14 days. Due to its late elevation, LDH is not practically useful for the acute diagnosis AMI.
B-type natriuretic peptide (BNP) is not recommended as a diagnostic marker for MI itself. Instead, BNP is more valuable for risk stratification, particularly in patients diagnosed with MI who subsequently develop heart failure.
Cardiac Imaging
Cardiac angiography is an invasive imaging modality used to visualize the coronary arteries directly. It is essential for performing percutaneous coronary intervention (PCI) and for identifying the location and severity of obstructions in the coronary vessels. Angiography plays a critical role in both the diagnosis AMI and the subsequent therapeutic intervention in STEMI and high-risk NSTEMI patients.
Echocardiography, both transthoracic and transesophageal, is a valuable non-invasive imaging technique used in diagnosis AMI. It allows for the assessment of regional wall motion abnormalities, which can indicate areas of myocardial ischemia or infarction. Echocardiography can also evaluate the degree of valvular abnormalities, such as ischemic mitral regurgitation, and detect complications like cardiac tamponade.
Treatment / Management
For all patients with suspected STEMI or NSTEMI, initial management, following the presumptive diagnosis AMI, should include immediate administration of nonenteric-coated, chewable aspirin at a loading dose of 162 mg to 325 mg.[12] Intravenous access should be established, and supplemental oxygen should be administered if oxygen saturation falls below 91%. Opioids may be considered for pain control, along with sublingual nitroglycerin, provided the patient’s blood pressure is within an acceptable range.[13][14][15]
The primary treatment strategy for STEMI, subsequent to diagnosis AMI, is immediate reperfusion. Emergent PCI is the preferred reperfusion method. Prior to PCI, patients should receive dual antiplatelet therapy, typically including intravenous heparin infusion and a P2Y12 inhibitor such as ticagrelor. Glycoprotein IIb/IIIa inhibitors or direct thrombin inhibitors may also be administered during the PCI procedure. If PCI cannot be performed within 90 minutes of STEMI diagnosis AMI, intravenous thrombolytic therapy should be initiated as an alternative reperfusion strategy.
In stable, asymptomatic patients with NSTEMI, after diagnosis AMI, the initial management is typically medical, focusing on antiplatelet agents and other guideline-directed medical therapies. However, PCI should be considered and can be performed within 48 hours of hospital admission if indicated based on risk stratification. A delayed PCI strategy in selected NSTEMI patients has been shown to potentially improve in-hospital mortality and reduce the length of hospital stay.
For NSTEMI patients who develop refractory ischemia or present with hemodynamic or electrical instability, emergent PCI is indicated, similar to the approach in STEMI after diagnosis AMI.
Before discharge following an acute MI, patients are typically prescribed several medications, including aspirin, a high-dose statin, a beta-blocker, and often an ACE inhibitor. These medications are crucial for secondary prevention after diagnosis AMI and treatment.
When PCI is the chosen treatment modality for acute MI, it is recommended to perform the procedure within 12 hours of symptom onset. If fibrinolytic therapy is selected as the primary reperfusion strategy, it should be initiated within 120 minutes of diagnosis AMI. In addition to reperfusion strategies, parenteral anticoagulation is recommended for all patients with acute MI, regardless of whether they undergo PCI or receive fibrinolytic therapy.
Differential Diagnosis
The differential diagnosis AMI is broad, as many conditions can mimic the symptoms of a heart attack. Conditions to consider include:
- Aortic dissection: A life-threatening condition involving a tear in the aorta’s inner layer, potentially obstructing blood flow.
- Pericarditis: Inflammation of the pericardium, which can cause chest pain similar to AMI.
- Acute gastritis: Inflammation of the stomach lining causing upper abdominal pain that may be mistaken for cardiac chest pain.
- Acute cholecystitis: Gallbladder inflammation causing right upper quadrant pain that can radiate to the chest.
- Asthma: Acute asthma exacerbation can cause chest tightness and shortness of breath, mimicking cardiac symptoms.
- Esophagitis: Inflammation of the esophagus, often due to GERD, can cause chest pain.
- Myocarditis: Inflammation of the heart muscle presenting with chest pain and AMI-like symptoms.
- Pneumothorax: A collapsed lung causing sudden chest pain and breathing difficulty.
- Pulmonary embolism: Blockage of a pulmonary artery by a blood clot, leading to chest pain and shortness of breath.
Prognosis
AMI carries a significant risk of mortality, especially outside of the hospital setting. Data indicate that at least one-third of patients die before reaching the hospital, and an additional 40% to 50% do not survive upon arrival. Furthermore, 5% to 10% of patients will die within the first year following an MI. Accurate and timely diagnosis AMI followed by appropriate treatment is crucial to improving these statistics.
The prognosis of AMI is closely related to the extent of myocardial damage. Patients who receive early reperfusion therapy, such as thrombolysis within 30 minutes of arrival or PCI within 90 minutes, generally have better outcomes. Preserved ejection fraction is also associated with better prognosis compared to reduced ejection fraction.
Post-MI medical management is vital for long-term prognosis. Initiating medications such as aspirin, beta-blockers, and ACE inhibitors is standard practice to prevent recurrent cardiovascular events after diagnosis AMI.
Factors that negatively impact prognosis include:
- Diabetes mellitus
- Advanced age
- Prior history of MI, peripheral vascular disease, or stroke
- Delayed reperfusion
- Reduced ejection fraction (the strongest predictor)
- Congestive heart failure
- Elevated C-reactive protein and BNP levels
- Depression
Readmission rates are high, with approximately 50% of patients being readmitted within the first 12 months after an initial MI. Overall prognosis is influenced by factors such as ejection fraction, age, and comorbidities. Patients who do not undergo revascularization procedures generally have poorer outcomes compared to those who do. The most favorable prognosis is observed in patients who achieve early and successful reperfusion and maintain preserved left ventricular function.[16][17][18]
Complications
Complications following diagnosis AMI and the acute phase can be significant and include:
- New-onset mitral regurgitation
- Ventricular septal rupture
- Left ventricular aneurysm
- Arrhythmias
- Systemic emboli
Postoperative and Rehabilitation Care
Cardiac rehabilitation is an essential component of recovery for patients following diagnosis AMI and treatment. Research has consistently shown that cardiac rehabilitation significantly improves quality of life, reduces disability, and decreases mortality rates.[19][20]
The rehabilitation process should be individualized, taking into account each patient’s specific needs, available resources, goals, and pre- and post-MI physical abilities. Collaboration between rehabilitation therapists and the interprofessional care team is crucial for ensuring continuity of care.[19][21]
Cardiac rehabilitation is also effective in reducing future cardiovascular risk factors in individuals post-AMI. Long-term follow-up studies demonstrate that cardiac rehabilitation participation can reduce the risk of subsequent cardiovascular events.[22]
Deterrence and Patient Education
For individuals experiencing symptoms suggestive of AMI, patient education is paramount. Recommended actions include:
- Seeking immediate medical attention for symptoms such as chest pain, shortness of breath, nausea, or lightheadedness by going to the nearest emergency department.
- Contacting emergency services if nitroglycerin does not provide symptom relief.
- Adhering to a low-salt diet to manage blood pressure and reduce cardiac workload.
- Enrolling in a cardiac rehabilitation program designed to support recovery from cardiac conditions like AMI.
- Smoking cessation, as smoking is a major cardiovascular risk factor.
- Maintaining medication adherence.
Enhancing Healthcare Team Outcomes
Optimal management of AMI requires a collaborative interprofessional team approach, crucial from initial diagnosis AMI through long-term care. In addition to the cardiologist, the team typically includes a cardiac surgeon, interventional cardiologist, intensivist, cardiac rehabilitation specialist, critical care and cardiology nurses, and physical therapists. Given the life-threatening nature of AMI, patient education about symptom recognition and the importance of seeking immediate medical attention is a top priority. Pharmacists, nurse practitioners, and primary care providers play vital roles in educating patients on nitroglycerin administration and when to seek emergency care if symptoms persist despite medication.
Time is critical in AMI management, and rapid reperfusion is essential. The care team’s initial assessment must be prompt, with immediate cardiology consultation. The cardiologist evaluates the patient, considering symptom duration and contraindications, to determine the most appropriate treatment strategy, which may involve thrombolysis or PCI to restore coronary blood flow. Accurate and rapid diagnosis AMI is the first critical step in this process.
Patients with AMI require close monitoring and specialized care in the ICU. ICU nurses are crucial for monitoring vital signs, administering medications, assessing for complications, and promptly communicating any abnormal clinical signs or laboratory findings to the interprofessional team.
Avoiding premature discharge is important as complications of MI can arise up to a week after the initial event. The interprofessional team must collaborate to ensure patients are stabilized, appropriately monitored, and thoroughly educated about signs and symptoms that may indicate worsening or recurrent MI.
Nurses are pivotal in patient education regarding risk factor modification for coronary artery disease. This education includes lifestyle changes, medication adherence, and ongoing monitoring of blood pressure, cholesterol, and blood sugar levels.
The involvement of a social worker or case manager is beneficial in facilitating home care arrangements, coordinating cardiac rehabilitation programs, and addressing any support service needs patients may have at home.
Pharmacists play a crucial role in medication management, providing education on proper dosing, potential adverse effects, drug interactions, and medication adherence to optimize treatment outcomes post diagnosis AMI.
Following discharge, patient participation in cardiac rehabilitation, adoption of a healthy diet, smoking cessation, alcohol abstinence, weight management (if needed), and control of cholesterol and blood glucose levels are critical. Patient education on the importance of medication compliance for blood pressure and cholesterol management is also essential.[23][24][25] Pharmacists review prescribed medications, check for interactions, and reinforce patient education on medication adherence.
Review Questions
Figure
Specimen of myocardial infarction showing damage to the left ventricle and interventricular septum, important anatomical considerations in diagnosis AMI.
Figure
Heart attack warning signs in women, highlighting the need for diverse diagnostic approaches for accurate diagnosis AMI in all populations.
Figure
ECG with Pardee waves indicative of acute myocardial infarction, a key diagnostic tool for diagnosis AMI.
Figure
Transesophageal Echocardiography demonstrating acute ECG segment elevation mimicking myocardial infarction in a patient with pulmonary embolism, underscoring the importance of differential diagnosis AMI.
References
1.Nascimento BR, Brant LCC, Marino BCA, Passaglia LG, Ribeiro ALP. Implementing myocardial infarction systems of care in low/middle-income countries. Heart. 2019 Jan;105(1):20-26. [PubMed: 30269080]
2.Barberi C, van den Hondel KE. The use of cardiac troponin T (cTnT) in the postmortem diagnosis of acute myocardial infarction and sudden cardiac death: A systematic review. Forensic Sci Int. 2018 Nov;292:27-38. [PubMed: 30269044]
3.Alaour B, Liew F, Kaier TE. Cardiac Troponin – diagnostic problems and impact on cardiovascular disease. Ann Med. 2018 Dec;50(8):655-665. [PubMed: 30265127]
4.Massberg S, Polzin A. [Update ESC-Guideline 2017: Dual Antiplatelet Therapy]. Dtsch Med Wochenschr. 2018 Aug;143(15):1090-1093. [PubMed: 30060279]
5.Scheen AJ. [From atherosclerosis to atherothrombosis : from a silent chronic pathology to an acute critical event]. Rev Med Liege. 2018 May;73(5-6):224-228. [PubMed: 29926559]
6.Berg DD, Wiviott SD, Braunwald E, Guo J, Im K, Kashani A, Gibson CM, Cannon CP, Morrow DA, Bhatt DL, Mega JL, O’Donoghue ML, Antman EM, Newby LK, Sabatine MS, Giugliano RP. Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 Nov 07;39(42):3810-3820. [PMC free article: PMC6220126] [PubMed: 30239711]
7.Deng D, Liu L, Xu G, Gan J, Shen Y, Shi Y, Zhu R, Lin Y. Epidemiology and Serum Metabolic Characteristics of Acute Myocardial Infarction Patients in Chest Pain Centers. Iran J Public Health. 2018 Jul;47(7):1017-1029. [PMC free article: PMC6119561] [PubMed: 30182001]
8.Haig C, Carrick D, Carberry J, Mangion K, Maznyczka A, Wetherall K, McEntegart M, Petrie MC, Eteiba H, Lindsay M, Hood S, Watkins S, Davie A, Mahrous A, Mordi I, Ahmed N, Teng Yue May V, Ford I, Radjenovic A, Welsh P, Sattar N, Oldroyd KG, Berry C. Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights. JACC Cardiovasc Imaging. 2019 Jun;12(6):993-1003. [PMC free article: PMC6547246] [PubMed: 30031700]
9.Alquézar-Arbé A, Sanchís J, Guillén E, Bardají A, Miró Ò, Ordóñez-Llanos J. Cardiac troponin measurement and interpretation in the diagnosis of acute myocardial infarction in the emergency department: a consensus statement. Emergencias. 2018 Oct;30(5):336-349. [PubMed: 30260119]
10.Perera M, Aggarwal L, Scott IA, Logan B. Received care compared to ADP-guided care of patients admitted to hospital with chest pain of possible cardiac origin. Int J Gen Med. 2018;11:345-351. [PMC free article: PMC6128279] [PubMed: 30214268]
11.Riley RF, Miller CD, Russell GB, Soliman EZ, Hiestand BC, Herrington DM, Mahler SA. Usefulness of Serial 12-Lead Electrocardiograms in Predicting 30-Day Outcomes in Patients With Undifferentiated Chest Pain (the ASAP CATH Study). Am J Cardiol. 2018 Aug 01;122(3):374-380. [PubMed: 30196932]
12.Jneid H, Addison D, Bhatt DL, Fonarow GC, Gokak S, Grady KL, Green LA, Heidenreich PA, Ho PM, Jurgens CY, King ML, Kumbhani DJ, Pancholy S. 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2017 Oct 17;70(16):2048-2090. [PubMed: 28943066]
13.Larson EA, German DM, Shatzel J, DeLoughery TG. Anticoagulation in the cardiac patient: A concise review. Eur J Haematol. 2019 Jan;102(1):3-19. [PubMed: 30203452]
14.Bath PM, Woodhouse LJ, Appleton JP, Beridze M, Christensen H, Dineen RA, Flaherty K, Duley L, England TJ, Havard D, Heptinstall S, James M, Kasonde C, Krishnan K, Markus HS, Montgomery AA, Pocock S, Randall M, Ranta A, Robinson TG, Scutt P, Venables GS, Sprigg N. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. Health Technol Assess. 2018 Aug;22(48):1-76. [PMC free article: PMC6139477] [PubMed: 30179153]
15.Adamski P, Adamska U, Ostrowska M, Navarese EP, Kubica J. Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. Expert Opin Pharmacother. 2018 Sep;19(13):1415-1425. [PubMed: 30132731]
16.Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, Torzewski J, Williams J, Lawson W, Broderick TM, Kabour A, Piegari G, Cavendish J, Bertolet B, Choi JW, Marx SO, Généreux P, Kereiakes DJ., ABSORB IV Investigators. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 2018 Oct 27;392(10157):1530-1540. [PubMed: 30266412]
17.Lopes RD, de Barros E Silva PGM, de Andrade Jesuíno I, Santucci EV, Barbosa LM, Damiani LP, Nakagawa Santos RH, Laranjeira LN, Dall Orto FTC, Beraldo de Andrade P, de Castro Bienert IR, Alexander JH, Granger CB, Berwanger O. Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial. JAMA Cardiol. 2018 Nov 01;3(11):1113-1118. [PMC free article: PMC6583055] [PubMed: 30264159]
18.Choi AR, Jeong MH, Hong YJ, Sohn SJ, Kook HY, Sim DS, Ahn YK, Lee KH, Cho JY, Kim YJ, Cho MC, Kim CJ., other Korea Acute Myocardial Infarction Registry Investigators. Clinical characteristics and outcomes in acute myocardial infarction patients with versus without any cardiovascular risk factors. Korean J Intern Med. 2019 Sep;34(5):1040-1049. [PMC free article: PMC6718753] [PubMed: 30257551]
19.Piotrowicz R, Wolszakiewicz J. Cardiac rehabilitation following myocardial infarction. Cardiol J. 2008;15(5):481-7. [PubMed: 18810728]
20.Ruano-Ravina A, Pena-Gil C, Abu-Assi E, Raposeiras S, van ‘t Hof A, Meindersma E, Bossano Prescott EI, González-Juanatey JR. Participation and adherence to cardiac rehabilitation programs. A systematic review. Int J Cardiol. 2016 Nov 15;223:436-443. [PubMed: 27557484]
21.Contractor AS. Cardiac rehabilitation after myocardial infarction. J Assoc Physicians India. 2011 Dec;59 Suppl:51-5. [PubMed: 22624283]
22.Sjölin I, Bäck M, Nilsson L, Schiopu A, Leosdottir M. Association between attending exercise-based cardiac rehabilitation and cardiovascular risk factors at one-year post myocardial infarction. PLoS One. 2020;15(5):e0232772. [PMC free article: PMC7213725] [PubMed: 32392231]
23.Aeyels D, Seys D, Sinnaeve PR, Claeys MJ, Gevaert S, Schoors D, Sermeus W, Panella M, Bruyneel L, Vanhaecht K. Managing in-hospital quality improvement: An importance-performance analysis to set priorities for ST-elevation myocardial infarction care. Eur J Cardiovasc Nurs. 2018 Aug;17(6):535-542. [PubMed: 29448818]
24.Schwaab B. [Cardiac Rehabilitation]. Rehabilitation (Stuttg). 2018 Apr;57(2):117-126. [PubMed: 29216666]
25.El Hajj MS, Jaam MJ, Awaisu A. Effect of pharmacist care on medication adherence and cardiovascular outcomes among patients post-acute coronary syndrome: A systematic review. Res Social Adm Pharm. 2018 Jun;14(6):507-520. [PubMed: 28641999]
Disclosure: Oren Mechanic declares no relevant financial relationships with ineligible companies.
Disclosure: Michael Gavin declares no relevant financial relationships with ineligible companies.
Disclosure: Shamai Grossman declares no relevant financial relationships with ineligible companies.
